Pharmaceutical Headlines for December 15 ( Thursday )

• Ember Therapeutics Launches with $34 Million of Third Rock Ventures' Cash More...

• Covidien (COV) Plans Spin-off of Pharmaceuticals Business More...

• Cerulean Pharma Inc. Closes $15 Million Series D Financing More...

• Sartorius AG Closes Acquisition of the Biohit Liquid Handling Business More...

• Hunter Immunology Limited and Probiomics: Merger to Speed Development of Promising New Vaccine for COPD More...

• Enlight Biosciences Forms New Partnerships with AstraZeneca PLC (AZN) and Novo Nordisk A/S (NVO) More...

• Phylogica Ltd. and Pfizer Inc. (PFE) Complete First Stage of Peptide Vaccine Collaboration More...

• HCPro Partnering with TEMIS to Boost Power of New Compliance Products More...

• Atlas Venture and Shire plc (SHPGY) Enter Alliance to Invest in Innovative Early-Stage Rare Disease Therapies More...

• MorphoSys AG and Novozymes, Inc. (NZYMb.CO) Sign Long-Term Alliance on Slonomics(R) Technology for Industrial Biotechnology Applications More...

• Vertex Pharmaceuticals (MA) (VRTX) Taps Jeff Leiden as New CEO to Diversify Beyond Hepatitis C More...

• Mustard Tree Instruments Promotes Peter Cregger to Chief Operations Officer More...

• Agilent Technologies Inc. (A) Names Gooi Soon ChaiSenior Vice President, Order Fulfillment and Supply Chain More...

• Geisinger Health System President and CEO Dr. Glenn Steele Named Premier Healthcare Alliance Board of Directors Chairman More...

• Suzy Jones Joins the Patrys Limited (PATZF.PK) Board as a Non-Executive Director More...

• Arrowhead Research Corporation (ARWR) to Report Fiscal 2011 Fourth Quarter and Year-End Financial Results More...

• Acacia Research Corp. (ACTG) Subsidiary Enters into Settlement Agreement With SRU Biosystems, Inc. More...

• SciClone Pharmaceuticals, Inc. (SCLN) Announces Final Settlement of Stockholder Derivative Litigation More...

• Ipsen Announces $45 Million R&D Investment and Headquarters Relocation in 2012; Plans to Hire More...

• Eli Lilly and Company (LLY) Planning New Irish Biopharma Plant More...

• Trophos ALS Drug Fails Ph3 Trial More...

• Celgene International Sarl (CELG) Release: Phase III Study Evaluating REVLIMID® in Patients with High-Risk Smoldering Multiple Myeloma Presented at American Society of Hematology More...

• Amgen (AMGN) Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim) More...

• Threshold Pharmaceuticals, Inc. (THLD) Announces Promising Phase 1 Clinical Trial Results in Patients With Advanced Leukemias More...

• Celgene International Sarl (CELG) Release: Final Phase II Data Evaluating REVLIMID® and Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia More...

• VIVUS, Inc. (VVUS)' Experimental Diet Drug Keeps Weight Off for 2 Years More...

• Salix Pharmaceuticals, Ltd. (SLXP) Announces NDA Submission for Crofelemer for the Treatment of HIV-Associated Diarrhea More...

• ContraFect Corporation Completes Successful Pre-IND Meeting With FDA More...

• Merck & Co., Inc. (MRK) Chemists Use High-Tech Science to Combat Alzheimer's Disease Challenge More...

• Few Allergies in Unstressed Babies, Karolinska Institute Study More...

• Acupuncture Might Ease Chemotherapy Pain, Acupuncture in MedicineReveals More...

• Most Common Causes, Risk Factors for Stillbirth, University of Utah Study More...

• Meta-analysis of Five Clinical Trials Including Columbia Laboratories, Inc. (CBRX)' PREGNANT Study Published in American Journal of Obstetrics and Gynecology More...
Tags: ,

About author

Make it happen !!

0 comments

Leave a Reply